Skip to main content

Biopsy Procedure (NCT07140679)

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer: a one-minute explainerNCT071406791 min

Biopsy Procedure trial for Localized Colon Carcinoma (NCT07140679). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with completely removed stage two-B, two-C or three colon cancer that is mismatch-repair deficient or MSI-high. Treatment starts four to twelve weeks after surgery. Prior neoadjuvant treatment or checkpoint therapy is excluded.

The idea: give toripalimab infusions every three weeks for eight doses. It blocks the PD-1 immune brake to support T-cell attack. Researchers test whether this approach prevents recurrence and track side effects. Scans, blood tests and colonoscopy continue during follow-up.

This phase 2 study plans 40 patients. Oluwadunni Emiloju leads five recruiting Emory sites in Georgia.

Public record; not medical advice.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.